Adimab Scores Two Deals And Some Milestone Payments

Adimab had multiple announcements today, including therapeutic discovery deals with Innovent and also Celgene and the receipt of milestone payments from existing collaborators.

Under the terms of its deal with Innovent, Adimab will utilize its antibody discovery and optimization platform to identify a fully human therapeutic antibody against a target selected by Innovent. All initial product development, including manufacturing and clinical trials, will be coordinated by Innovent. Both companies will retain rights to develop and commercialize the therapeutic program in their respective geographic territories.

Innovent will retain rights for commercialization in China, with royalties owed to Adimab on product sales. Adimab will retain rights for commercialization in the United States, Europe, and Japan, with royalties owed to Innovent on product sales.

With Celgene, the partnership is broader. Adimab will generate therapeutic antibodies against multiple targets, and Celgene will have the right to develop and commercialize all resulting therapeutic antibodies.

For each target, Celgene has the right to research antibodies generated during the collaboration for potential use as therapeutic products. Under the terms of the agreement, Adimab will receive an up-front payment. In addition, for each target, Celgene will have the option to exclusively license antibodies generated during the collaboration. If Celgene exercises its option for a particular target, Adimab would receive license fees, clinical milestones, and royalties on therapeutic product sales.

In addition, Adimab reported the achievement of milestone payments from its ongoing collaborations with Eli Lilly and Kyowa Hakko Kirin. It relationship with Eli Lilly commenced in December 2010, and its partnership with Kyowa Hakko Kirin in January this year.


Genetic Engineering & Biotechnology News (GEN)Genetic Engineering & Biotechnology News (GEN)This article was reprinted from Genetic Engineering & Biotechnology News (GEN) with permission from Mary Ann Liebert, Inc., publishers. Genetic Engineering & Biotechnology News (GEN) has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, like news and analysis as well as blogs, podcasts, webinars, polls, videos, and application notes. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR